PDL BioPharma, Inc. (NASDAQ:PDLI) major shareholder Silver Point Capital L.P. bought 640,000 shares of the firm’s stock in a transaction that occurred on Monday, December 14th. The stock was purchased at an average cost of $2.62 per share, with a total value of $1,676,800.00. The acquisition was disclosed in a filing with the Securities & […]
→ Google 翻訳
PDL BioPharma, Inc. (NASDAQ:PDLI) Director David W. Gryska sold 75,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 3rd. The shares were sold at an average price of $2.52, for a total value of $189,000.00. Following the completion of the sale, the director now owns 30,337 shares in the company, […]
→ Google 翻訳
PDL BioPharma, Inc. (NASDAQ:PDLI)’s share price traded down 5.2% during trading on Monday . The company traded as low as $2.20 and last traded at $2.20. 755,649 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 1,182,237 shares. The stock had previously closed at $2.32. A number of […]
→ Google 翻訳
PDL BioPharma (NASDAQ:PDLI) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Earnings & Valuation This table compares PDL BioPharma and Acorda Therapeutics’ revenue, earnings per share […]
→ Google 翻訳
INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively "Noden") to Stanley Capital. The total value of the…
→ Google 翻訳
INCLINE VILLAGE, Nev., Aug. 31, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK…
→ Google 翻訳
INCLINE VILLAGE, Nev., Aug. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that holders of its 2.75% Convertible Senior Notes due in December 2021 (the "2021 Notes") and in December 2024 (the "2024 Notes" and together with the 2021…
→ Google 翻訳
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) Avenue Therapeutics Inc (NASDAQ: ATXI ) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) DarioHealth Corp (NASDAQ: DRIO ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Otonomy Inc (NASDAQ: OTIC ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Pacira Biosciences Inc (NASDAQ: PCRX ) PDL BioPharma Inc (NASDAQ: PDLI ) Principia Biopharma Inc (NASDAQ: PRNB ) Qiagen NV (NYSE: QGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Silk Road Medical Inc (NASDAQ: SILK ) Syros Pharmaceuticals Inc (NASDAQ: SYRS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 18) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Interpace Biosciences Inc (NASDAQ: IDXG )(announced receipt of letters from recently departed employees regarding billing and compliance issues) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Poseida Therapeutics, Inc. (NASDAQ: PSTX )( announced clinical hold on its Phase 1 prostate cancer study) Predictive Oncology Inc (NASDAQ: POAI ) Recro Pharma Inc (NASDAQ: REPH ) Unity Biotechnology Inc (NASDAQ: UBX ) Stocks In Focus Venrock Reports Purchase of 451K Unum Shares Unum Therapeutics Inc (NASDAQ: UMRX ) shares advanced after Venrock Healthcare Partners III L.P. said in a filing it has purchased 451,000 shares of Unum's common stock in a series of transactions effected between Aug. 14 and Aug. 18, bringing the total number of shares owned by the fund to 4.355 million The stock climbed 16.24% to $3.15 in after-hours trading.
→ Google 翻訳
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (announced introduction of AditxtScore for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biocept Inc (NASDAQ: BIOC ) (announced an agreement with Aegea for a highly sensitive PCR-based assay designed by the latter for detecting the COVID-19 virus) DarioHealth Corp (NASDAQ: DRIO ) Denali Therapeutics Inc (NASDAQ: DNLI )( announced selection of candidate to enter Phase 3 study in Parkinson's disease) Editas Medicine Inc (NASDAQ: EDIT )(moved on M&A speculation) Emergent Biosolutions Inc (NYSE: EBS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Natera Inc (NASDAQ: NTRA ) PDL BioPharma Inc (NASDAQ: PDLI ) Sangamo Therapeutics Inc (NASDAQ: SGMO ) (reacted to its second-quarter results) Shockwave Medical Inc (NASDAQ: SWAV ) SurModics, Inc. (NASDAQ: SRDX )(reacted to its second-quarter results) Twist Bioscience Corp (NASDAQ: TWST ) Unity Biotechnology Inc (NASDAQ: UBX ) Zoetis Inc (NYSE: ZTS ) (reacted to its second-quarter results) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 6) Nkarta Inc (NASDAQ: NKTX ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX )(announced its second-quarter results) Stocks In Focus Zosano Clinches Distribution Deal For Investigational Migraine Patch Zosano Pharma Corp (NASDAQ: ZSAN ) said it has partnered with Eversana commercialize and distribute Qtrypta in the U.S.
→ Google 翻訳
INCLINE VILLAGE, Nev., Aug. 6, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and six months ended June 30, 2020 and provides an update on important milestones achieved in the execution of its monetization plan: "I…
→ Google 翻訳
INCLINE VILLAGE, Nev., July 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its second quarter 2020 financial results for the period ended June 30, 2020, on Thursday, August 6, 2020, after market close. PDL's management…
→ Google 翻訳
In this article we will take a look at whether hedge funds think PDL BioPharma Inc. (NASDAQ:PDLI) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional
→ Google 翻訳
INCLINE VILLAGE, Nev., May 21, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq:…
→ Google 翻訳
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
→ Google 翻訳
INCLINE VILLAGE, Nev., May 18, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem")…
→ Google 翻訳
INCLINE VILLAGE, Nev., May 7, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three months ended March 31, 2020 and provides a business update: In March 2020, the Company announced that its Board of Directors (the "Board")…
→ Google 翻訳
INCLINE VILLAGE, Nev., May 5, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that the Company's Board of Directors has approved a distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem")…
→ Google 翻訳
INCLINE VILLAGE, Nev., April 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its first quarter 2020 financial results for the period ended March 31, 2020, on Thursday, May 7, 2020, after market close. PDL's management…
→ Google 翻訳
INCLINE VILLAGE, Nev., Feb. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced it has entered into a cooperation agreement with Engine Capital Management LP (together with its affiliates, "Engine"), which owns approximately 5.5% of the…
→ Google 翻訳
INCLINE VILLAGE, Nev., Dec. 13, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange agreements pursuant to which it will exchange $119.3 million in aggregate principal amount of…
→ Google 翻訳
PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.
→ Google 翻訳
INCLINE VILLAGE, Nev., Nov. 6, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2019: Third Quarter Financial Highlights Total revenues were $44.2 million, including $20.3 million…
→ Google 翻訳
INCLINE VILLAGE, Nev., Oct. 30, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter 2019 financial results for the period ended September 30, 2019, on Wednesday, November 6, 2019, after market close. PDL's…
→ Google 翻訳
PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues
→ Google 翻訳